Pacira BioSciences Quarterly Income Statement
NASDAQ: PCRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pacira BioSciences revenue and earnings
In the quarter ended Jun 30, 2026, Pacira BioSciences generated $192.4 million in revenue, up 6.2% from the same quarter a year earlier. Net income was $4.7 million, for a net margin of 2.4% versus a median of 1.6% in the prior 5 quarters. Gross margin was 77.0% (down from 77.4%) and operating margin 2.2%.
Diluted earnings per share came in at $0.12.
Summary generated from market data by MetaCap's automated system. Methodology
Pacira BioSciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192.40M | 177.38M | 196.87M | 179.52M | 181.10M | 168.92M | 187.25M | 168.57M | 178.02M | 167.12M | 181.24M | 163.93M |
| Revenue growth (YoY) | +6.24% | +5.00% | +5.14% | +6.49% | +1.73% | +1.08% | +3.32% | +2.83% | +5.05% | +4.23% | +5.40% | -2.11% |
| Cost of Revenue | 44.16M | 36.41M | 40.30M | 34.28M | 40.87M | 34.31M | 39.89M | 38.86M | 44.26M | 47.42M | 47.69M | 39.75M |
| Gross Profit | 148.24M | 140.96M | 156.57M | 145.24M | 140.23M | 134.62M | 147.37M | 129.71M | 133.76M | 119.70M | 133.55M | 124.18M |
| Operating Expenses | 143.97M | 134.06M | 154.23M | 138.88M | 131.73M | 132.63M | 122.66M | 269.24M | 105.52M | 106.49M | 100.38M | 106.45M |
| Research & Development | 30.24M | 28.07M | 37.45M | 25.97M | 28.20M | 25.34M | 23.90M | 19.10M | 20.34M | 18.24M | 19.46M | 20.83M |
| Selling, General & Admin | 91.81M | 93.94M | 101.61M | 91.80M | 88.58M | 86.78M | 79.61M | 74.33M | 68.13M | 72.03M | 65.80M | 67.95M |
| Operating Income | 4.27M | 6.90M | 2.34M | 6.36M | 8.50M | 1.99M | 24.70M | -139.53M | 28.24M | 13.21M | 33.17M | 17.72M |
| Interest Expense | 3.62M | 3.70M | 3.89M | 4.28M | 4.70M | 4.58M | 4.68M | 4.69M | 3.88M | 3.32M | 3.39M | 3.46M |
| Other Income (Expense) | -1.71M | -1.90M | -1.77M | 3.16M | -10.43M | 6.72M | 822.00K | 671.00K | 8.34M | 428.00K | 552.00K | -1.12M |
| Pretax Income | 2.56M | 5.00M | 571.00K | 9.52M | -1.93M | 8.71M | 25.53M | -138.86M | 36.58M | 13.64M | 33.72M | 16.60M |
| Income Tax | -2.10M | 2.08M | -1.07M | 4.09M | 2.92M | 3.89M | 9.48M | 4.61M | 17.70M | 4.66M | 8.85M | 5.74M |
| Net Income | 4.65M | 2.92M | 1.64M | 5.43M | -4.85M | 4.81M | 16.04M | -143.47M | 18.89M | 8.98M | 24.87M | 10.86M |
| Net Income growth (YoY) | — | -39.40% | -89.79% | — | -125.66% | -46.41% | -35.50% | -1421.29% | -26.69% | — | — | — |
| EPS (Basic) | 0.12 | 0.07 | 0.05 | 0.12 | -0.11 | 0.10 | 0.36 | -3.11 | 0.41 | 0.19 | 0.55 | 0.23 |
| EPS (Diluted) | 0.12 | 0.07 | 0.05 | 0.12 | -0.11 | 0.10 | 0.38 | -3.11 | 0.39 | 0.19 | 0.58 | 0.23 |
| Shares Outstanding (Basic) | 39.46M | 40.46M | — | 44.04M | 45.46M | 46.27M | — | 46.13M | 46.17M | 46.50M | — | 46.42M |
| Shares Outstanding (Diluted) | 40.30M | 40.91M | — | 44.46M | 45.46M | 46.53M | — | 46.13M | 50.54M | 52.19M | — | 52.07M |
| EBITDA | 25.56M | 28.23M | 23.68M | 27.55M | 35.82M | 23.16M | 45.95M | -119.27M | 47.10M | 31.64M | 51.65M | 36.15M |
| Gross Margin | 77.05% | 79.47% | 79.53% | 80.91% | 77.43% | 79.69% | 78.70% | 76.95% | 75.14% | 71.63% | 73.69% | 75.75% |
| Operating Margin | 2.22% | 3.89% | 119.00% | 3.54% | 4.69% | 118.00% | 13.19% | -82.77% | 15.86% | 7.91% | 18.30% | 10.81% |
| Net Margin | 2.42% | 1.64% | 83.00% | 3.03% | -2.68% | 2.85% | 8.57% | -85.11% | 10.61% | 5.37% | 13.72% | 6.62% |
This table shows 12 quarterly periods of Pacira BioSciences's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PCRX's reporting calendar. What is a income statement?